Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

Area of Science:

• Pharmacology
• Clinical Research Methodology

Background:

• Effectiveness studies (phase IV) are increasingly important in evidence-based medicine.
• They aim for broader generalizability than phase III studies due to less restrictive designs.
• Phase IV studies supplement phase III trial data on psychopharmaceuticals like antipsychotics.

Purpose of the Study:

• To critically evaluate recently published effectiveness studies on antipsychotic treatment for schizophrenia.
• To highlight methodological pitfalls in phase IV studies and their impact on results.
• To question the conclusions drawn from these studies based on design limitations.

Main Methods:

• Analysis of methodological aspects of published effectiveness studies.
• Identification of common design issues in phase IV studies (e.g., patient selection, co-medication, outcome criteria, randomization, blinding).
• Comparison of findings from effectiveness studies with established phase III trial data.

Main Results:

• Effectiveness studies, despite broader generalizability, possess inherent methodological problems.
• Confounding factors and design flaws (e.g., insensitive outcomes, unblinded treatments) increase result variance.
• Results from phase IV studies cannot falsify phase III trial findings.

Conclusions:

• Effectiveness studies on antipsychotics require cautious interpretation due to significant methodological challenges.
• Awareness of design issues is crucial for understanding the limitations of phase IV study results.
• The validity of conclusions from recent schizophrenia antipsychotic effectiveness trials is questioned due to severe methodological pitfalls.